Fig. 11
From: Radiosensitizing high-Z metal nanoparticles for enhanced radiotherapy of glioblastoma multiforme
(Reproduced with permission from reference: [37], copyright 2015 Springer Science + Business Media New York)
Radiosensitivity enhancement of radiosesistant human GBM by cetuximab-IONP treatment. a Representative immunofluorescence image of U87MGEGFRvIII cells after treatment of four comparison groups (0.3 mg/mL of PBS, IONPs, cetuximab and cetuximab-IONPs) with ionizing irradiation (IR) dose of 2 Gy and incubation for 24 h. b ROS detection of above treatment with ionizing irradiation dose of 10 Gy and incuation for 24 h. c Hypointense T2-weighted MRI images of control and cetuximab-IONPs + IR groups. White arrows: EGFRvIII-expressing human xenograft, red arrows: convection-enhanced delivery(CED) of cetuximab-IONPs. d Kaplan–Meier survival curve for U87MG EGFRvIII inplanted mice. Three groups are involved as comparison: no treatment (control); combination of cetuximab and IR treatment (cetuximab + IR); and cetuximab-IONPs with subsequent IR (cet-IONPs + IR). Concentration of cetuximab was 0.3 mg/mL and IR dose were 10 Gy × 2